{"type":"Disease","alternate_names":["Atelosteogenesis type 2","NEONATAL OSSEOUS DYSPLASIA I","Neonatal osseous dysplasia 1"],"medgen_id":"C1850554","keywords":[],"public_definition":"Clinical features of atelosteogenesis type 2 (AO2) include rhizomelic limb shortening with normal-sized skull, hitchhiker thumbs, small chest, protuberant abdomen, cleft palate, and distinctive facial features (midface retrusion, depressed nasal bridge, epicanthus, micrognathia). Other typical findings are ulnar deviation of the fingers, gap between the first and second toes, and clubfoot. AO2 is usually lethal at birth or shortly thereafter due to pulmonary hypoplasia and tracheobronchomalacia. However, it exists in a continuous phenotypic spectrum with diastrophic dysplasia, and long-term survivors have been reported.","attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301493\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1317\",\"@Source\":\"BookShelf\"}]}}","gard_id":"8329","id":"558","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009727\"}","{\"db\":\"OMIM\",\"id\":\"256050\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"56304\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Atelosteogenesis+Type+2/641\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Atelosteogenesis type 2\"}","{\"db\":\"OMIM\",\"id\":\"256050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEONATAL OSSEOUS DYSPLASIA I\"}","{\"db\":\"OMIM\",\"id\":\"256050\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AOII\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8329\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009727\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1317\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"256050\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"AO2","alternate_symbols":["AOII"],"name":"Atelosteogenesis type II"}
{"type":"Disease","alternate_names":["Coats disease","Retinal telangiectasis"],"medgen_id":"C0154832","keywords":[],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301506\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1331\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110944\",\"@Source\":\"pmc\"}}]}","gard_id":"6121","id":"1522","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007898\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010269\"}","{\"db\":\"OMIM\",\"id\":\"300216\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"190\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010269\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Coats disease\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6121\",\"ref_field\":\"gard_id\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007898\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"25506007\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"name":"Exudative retinopathy"}
{"type":"Disease","alternate_names":["Pigmentary retinal deposits","Rarefaction of retinal pigmentation","Retinal pigment clumping"],"medgen_id":"C4551715","keywords":[],"attribute_content":[],"id":"21761","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000580\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007702\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007821\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007869\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007961\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008010\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000580\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pigmentary retinal deposits\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000580\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Retinal pigment clumping\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000580\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"name":"Pigmentary retinopathy"}
{"type":"Finding","alternate_names":["Hypertriglyceridaemia","Increased circulating Tg levels","Increased plasma Tg levels","Increased plasma triglycerides","Increased serum triglycerides","Increased triglycerides"],"medgen_id":"C0813230","keywords":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"ES, 2012\",\"@Type\":\"practice guideline\",\"ID\":[{\"$\":\"22962670\",\"@Source\":\"PubMed\"},{\"$\":\"3431581\",\"@Source\":\"pmc\"}]}}","id":"22885","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002155\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003082\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008174\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008332\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0005347\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002155\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased circulating Tg levels\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002155\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased plasma Tg levels\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002155\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased plasma triglycerides\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002155\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased serum triglycerides\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002155\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased triglycerides\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002155\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"name":"Hypertriglyceridemia"}
{"type":"Disease","alternate_names":["HUPRA SYNDROME","HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSIS SYNDROME"],"medgen_id":"C3151209","keywords":[],"public_definition":"HUPRA syndrome is a severe autosomal recessive multisystem disorder characterized by onset in infancy of progressive renal failure leading to electrolyte imbalances, metabolic alkalosis, pulmonary hypertension, hypotonia, and delayed development. Affected individuals are born prematurely (summary by Belostotsky et al., 2011).","attribute_content":[],"id":"16063","xrefs":["{\"db\":\"OMIM\",\"id\":\"613845\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"363694\"}","{\"db\":\"OMIM\",\"id\":\"613845\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HUPRA SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"612804.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSIS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"612804.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSIS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"613845\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSIS SYNDROME\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hyperuricemia%2C+pulmonary+hypertension%2C+renal+failure%2C+and+alkalosis/8608\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613845\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613845\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"HUPRAS","alternate_symbols":[],"name":"Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis"}
{"type":"Disease","alternate_names":["Criswick-Schepens syndrome"],"medgen_id":"C1851402","keywords":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301326\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1147\",\"@Source\":\"BookShelf\"}]}}","id":"1787","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007589\"}","{\"db\":\"OMIM\",\"id\":\"133780\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"891\"}","{\"db\":\"Orphanet\",\"id\":\"90050\"}","{\"db\":\"OMIM\",\"id\":\"133780\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"EVR1","alternate_symbols":["FZD4","LRP5"],"name":"Exudative vitreoretinopathy 1"}
{"type":"Disease","alternate_names":["Desmin-related myopathies with Mallory bodies","Minicore myopathy, severe classic form","Multicore myopathy, severe classic form","Multiminicore disease, severe classic form","Muscular dystrophy, congenital, merosin positive with early spine rigidity","Rigid spine muscular dystrophy-1","Rigid spine syndrome"],"medgen_id":"C0410180","ghr_links":"rigid spine muscular dystrophy","keywords":[],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301467\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1290\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Int'l SCC for CMD, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21078917\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301468\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1291\",\"@Source\":\"BookShelf\"}]}]}","id":"4109","xrefs":["{\"db\":\"OMIM\",\"id\":\"602771\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"97244\"}","{\"db\":\"OMIM\",\"id\":\"602771\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MDRS1\"}","{\"db\":\"OMIM\",\"id\":\"602771\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RSS\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"rigid-spine-muscular-dystrophy\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Eichsfeld+type+congenital+muscular+dystrophy/8301\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"240063002\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602771\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"RSMD1","alternate_symbols":["MDRS1","RSS","SEPN1-RM"],"name":"Eichsfeld type congenital muscular dystrophy"}
{"type":"Disease","alternate_names":[],"medgen_id":"C1621958","keywords":[],"attribute_content":[],"id":"30059","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012174\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100843\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012174\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137800\",\"ref_field\":\"symbol\"}"],"symbol":"GBM","alternate_symbols":[],"name":"Glioblastoma multiforme"}
{"type":"Disease","alternate_names":["GM2 gangliosidosis, type 1","HexA deficiency","Hexosaminidase A Deficiency","Hexosaminidase alpha-subunit deficiency (variant B)","Sphingolipidosis, Tay-Sachs"],"medgen_id":"C0039373","keywords":[],"public_definition":"Hexosaminidase A deficiency results in a group of neurodegenerative disorders caused by intralysosomal storage of the specific glycosphingolipid, GM2 ganglioside. The prototype hexosaminidase A deficiency is Tay-Sachs disease, also known as the acute infantile variant. Tay-Sachs disease is characterized by progressive weakness, loss of motor skills, decreased attentiveness, and increased startle response beginning between ages three and six months with progressive evidence of neurodegeneration including: seizures, blindness, spasticity, eventual total incapacitation, and death, usually before age four years. The juvenile (subacute), chronic, and adult-onset variants of hexosaminidase A deficiency have later onsets, slower progression, and more variable neurologic findings, including: progressive dystonia, spinocerebellar degeneration, motor neuron disease, and, in some individuals with adult-onset disease, a bipolar form of psychosis.","attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301397\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1218\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"18197057\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACOG, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19888064\",\"@Source\":\"PubMed\"}}]}","gard_id":"7737","id":"6027","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010100\"}","{\"db\":\"OMIM\",\"id\":\"272800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"845\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7737\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Tay+Sachs+disease/7008\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"tay-sachs-disease\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"111385000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1218\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"272800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"TSD","alternate_symbols":[],"name":"Tay-Sachs disease"}
{"type":"Disease","alternate_names":["CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE 2","Calcium gout","Calcium gout, familial","Calcium pyrophosphate arthropathy","Calcium pyrophosphate arthropathy, familial","Calcium pyrophosphate dihydrate deposition disease","Chondrocalcinosis 2","Chondrocalcinosis familial articular","Pseudogout, familial"],"medgen_id":"C0856830","keywords":[],"attribute_content":[],"gard_id":"1292","id":"892","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007319\"}","{\"db\":\"OMIM\",\"id\":\"118600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1416\"}","{\"db\":\"OMIM\",\"id\":\"118600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE 2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Chondrocalcinosis+2/1359\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Chondrocalcinosis 2\"}","{\"db\":\"OMIM\",\"id\":\"118600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CCAL2\"}","{\"db\":\"OMIM\",\"id\":\"118600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CPPDD\"}","{\"db\":\"OMIM\",\"id\":\"118600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CPPDD2\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1292\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007319\",\"ref_field\":\"name\"}"],"alternate_symbols":["CCAL2","CPPDD","CPPDD2"],"name":"Familial calcium pyrophosphate deposition"}
{"type":"Disease","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"medgen_id":"C0002986","keywords":[],"public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000591289\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"}]}"],"content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","gard_id":"6400","id":"1790","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"alternate_symbols":[],"disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","name":"Fabry disease"}
{"type":"Disease","alternate_names":["Non-small cell lung carcinoma"],"medgen_id":"C0007131","keywords":[],"public_definition":"Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of the affected cells when viewed under a microscope. Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 percent.Small cell lung cancer grows quickly and in more than half of cases the cancer has spread beyond the lung by the time the condition is diagnosed. Small cell lung cancer often metastasizes, most commonly to the liver, brain, bones, and adrenal glands (small hormone-producing glands located on top of each kidney). After diagnosis, most people with small cell lung cancer survive for about 1 year; less than seven percent survive 5 years.Non-small cell lung cancer is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Adenocarcinoma arises from the cells that line the small air sacs (alveoli) located throughout the lungs. Squamous cell carcinoma arises from squamous cells that line the passages leading from the windpipe (trachea) to the lungs (bronchi). Large cell carcinoma arises from epithelial cells that line the lungs. Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. The 5-year survival rate for people with non-small cell lung cancer is usually between 11 and 17 percent; it can be lower or higher depending on the subtype and stage of the cancer.","attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"FDA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24868098\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Cooper et al., 2014\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"24673736\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"KCPSG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24627688\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"KCPSG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23667368\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NICE, 2013\",\"@Type\":\"practice guideline\",\"URL\":{\"$\":\"https://www.nice.org.uk/guidance/dg9\"}},{\"@Abbrev\":\"AHRQ, 2013\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin\"},\"URL\":{\"$\":\"https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id90TA.pdf\"}}]}","id":"7728","disease_mechanism_id":"283","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0030358\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0005233\"}","{\"db\":\"MeSH\",\"id\":\"D002289\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0030358\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Non-small cell lung carcinoma\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569448\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569877\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569888\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569891\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000571363\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000576363\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591875\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Non-small+cell+lung+cancer/5250\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0030358\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"254637007\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"lung-cancer\",\"ref_field\":\"public_definition\"}"],"symbol":"NSCLC","alternate_symbols":[],"disease_mechanism":"Other","name":"Non-small cell lung cancer"}
